华东医药(000963.SZ):公司申报的依达拉奉片上市许可申请获得受理
Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Sino-American Huadong, received the Acceptance Notice from the National Medical Products Administration for the marketing authorization application of Edaravone Tablets (R&D code: TTYP01) for the treatment of acute ischemic stroke [1] Group 1 - Sino-American Huadong has signed an exclusive licensing agreement with Ausgen Biotech, obtaining exclusive rights for all indications of TTYP01 in mainland China, Hong Kong, Macau, and Taiwan [1]